Raphas: Korean regulator returns Phase 2b/3 trial application for allergic rhinitis immunotherapy DF19001
For reference only, not investment advice.This is a factual summary of a company filing. It is not a recommendation to buy, sell or hold any security. Read the original filing on DART before making any decision. Full disclaimer
What was filed
Raphas disclosed that the Ministry of Food and Drug Safety (MFDS) returned its application to start a Phase 2b/3 trial of DF19001, an immunotherapy for American house dust mite allergic rhinitis.
Key facts
| Product | DF19001, allergic rhinitis immunotherapy |
|---|---|
| Planned trial | Phase 2b/3, 52-week, multicentre, randomised, double-blind, placebo-controlled |
| Reason given | Request to supplement the trial protocol and data on manufacturing and quality of the investigational drug |
| Company's next step | Review the reasons and re-apply for IND approval |
| Date notified | 20 Nov 2026 |
Context
The company states the return relates to protocol and manufacturing/quality documents, not to the safety and immunogenicity data from its earlier Phase 1 trial.
Original filing: DART receipt no. 20261120900961 (Korean)
Figures are taken from the filing as submitted. KRW conversions use the exchange rate stated in the filing. Filings can be corrected later; the DART version prevails.